http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
간질환 병력이 없는 환자에게 처음 진단된 간세포암종에서 수술 후 조기다발성 재발을 보인 1예
최왕용 ( Wang Yong Choi ),장병국 ( Byoung Kuk Jang ),정우진 ( Woo Jin Chung ),황재석 ( Jae Seok Hwang ) 대한간암학회 2015 대한간암학회지 Vol.15 No.2
Hepatocellular carcinoma (HCC) have relatively well known causative factors such as chronichepatitis B, chronic hepatitis C, alcoholic liver disease, Non-alcoholic fatty liver disease (NAFLD), liver cirrhosis and so on. Recently, interesting reports that HCC in the absence of cirrhosis or other chronic liver disease and HCC associated with NAFLD and metabolic syndrome are increasing in USA. So far, there is no report about these issues in Korea. We present a 65 yearold obesity male who had no preceding chronic liver disease history. He was diagnosed as primary HCC and the mass was removed completely. However, HCC recurred shortly after operation. Multiple recurred HCC were treated with transcatheter arterial chemoembolization. (J Liver Cancer 2015;15:112-117)
위장관 ; 한국의 염증성 장질환과 자가면역성 간염 환자에서 Azathioprine의 부작용 비교
이유진 ( Yoo Jin Lee ),최왕용 ( Wang Yong Choi ),박경식 ( Kyung Sik Park ),김윤정 ( Yun Jung Kim ),조광범 ( Kwang Bum Cho ),김은수 ( Eun Soo Kim ),장병국 ( Byoung Kuk Jang ),정우진 ( Woo Jin Chung ),황재석 ( Jae Seok Hwang ) 대한소화기학회 2014 대한소화기학회지 Vol.64 No.6
Background/Aims: Azathioprine (AZA) has been widely used in the therapy of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). However, studies evaluating the adverse effects of AZA in these two diseases are lacking. The aim of this study was to compare the adverse effects of AZA in Korean IBD and AIH patients. Methods: Patients with IBD or AIH who were treated with AZA at Keimyung University Dongsan Medical Center (Daegu, Korea) between January 2002 and March 2011 were enrolled. Their medical records were reviewed retrospectively in terms of clinical characteristics and adverse effects of AZA. Results: A total of 139 IBD patients and 55 AIH patients were finally enrolled. Thirty IBD patients (21.6%) and eight AIH patients (14.5%) experienced adverse effects of AZA. In particular, the prevalence of leukopenia was significantly higher in the IBD group than in the AIH group (p=0.026). T474C mutation was observed in three of 10 patients who were assessed for thiopurine methyltransferase (TPMT) genotype. Conclusions: IBD patients are at increased risk for the adverse effects of AZA compared with AIH patients, of which leukopenia was the most commonly observed. Therefore, IBD patients receiving AZA therapy should be carefully monitored. (Korean J Gastroenterol 2014;64:348-355)